信号通路在骨髓瘤中的双重作用要求按细胞类型靶向配体-受体相互作用
研究纳入25例新诊断多发性骨髓瘤患者,分析免疫微环境内调控网络及其对疾病进展的影响。免疫细胞组成与表达谱分析显示B细胞区室差异与治疗反应相关,短进展时间患者的转录状态富集促B细胞分化和炎症反应通路。分子相互作用分析表明信号通路具双重作用,其预后意义取决于参与的细胞类型。
要点
- 25例新诊断骨髓瘤患者免疫微环境分析显示B细胞区室差异与治疗反应相关。
- 短进展时间患者转录状态富集促B细胞分化与炎症反应通路,可能提示免疫功能障碍。
- 信号通路可因参与细胞类型不同而与良好或不良预后相关。
核心结论
- 信号通路在骨髓瘤免疫微环境中具双重作用,其与良好或不良预后的关联取决于参与的细胞类型。
- 作者认为靶向配体-受体相互作用的治疗策略应考虑微环境组成及分子相互作用所涉及的具体细胞类型。
研究设计与样本
- 研究纳入25例新诊断多发性骨髓瘤患者,分析免疫区室内复杂调控网络及其对疾病进展的影响。
主要发现
- 免疫细胞组成与表达谱分析显示,B细胞区室存在与治疗反应相关的显著差异。
- 短进展时间患者的转录状态富集促B细胞分化与炎症反应通路,可能提示免疫功能障碍。
- 免疫微环境内分子相互作用分析显示信号通路具双重作用,可因参与细胞类型不同而与良好或不良预后相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Although most patients with multiple myeloma respond to treatment initially, therapy resistance develops almost invariably, and only a subset of patients show durable responses to immunomodulatory therapies. Although the immune microenvironment has been extensively studied in patients with myeloma, its composition is currently not used as prognostic markers in clinical routine. We hypothesized that the outcome of immune signaling pathway engagement can be highly variable, depending on which 2 cellular populations participate in this interaction. This would have important prognostic and therapeutic implications, suggesting that it is crucial for immune pathways to be targeted in a specific cellular context. To test this hypothesis, we investigated a cohort of 25 patients with newly diagnosed multiple myeloma. We examined the complex regulatory networks within the immune compartment and their impact on disease progression. Analysis of immune cell composition and expression profiles revealed significant differences in the B-cell compartment associated with treatment response. Transcriptional states in patients with short time to progression demonstrated an enrichment of pathways promoting B-cell differentiation and inflammatory responses, which may indicate immune dysfunction. Importantly, the analysis of molecular interactions within the immune microenvironment highlights the dual role of signaling pathways, which can either be associated with good or poor prognosis depending on the cell types involved. Our findings therefore argue that therapeutic strategies targeting ligand-receptor interactions should take into consideration the composition of the microenvironment and the specific cell types involved in molecular interactions.
引用
- Hernandez-Lopez P, Vijaykumar T, Anand P, et al. Dual role of signaling pathways in myeloma requires cell type-specific targeting of ligand-receptor interactions. Blood Adv. 2024. PMID: 38603572. doi:10.1182/bloodadvances.2023011463
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。